Transgene Biotek, one of India’s earliest biotechnology company, signalled its continued westward expansion with the signing of a Memorandum-of-Understanding (MoU) with Armour Therapeutics Inc. (Armour) of Toronto, Canada. Transgene and Armour are exploring a strategic relationship to co-develop Armour’s drug candidates for reproductive cancers. Armour’s lead anti-relax-in molecule, AT- 001, is being developed to treat hormone refractory prostate cancer.
The newly signed MoU with Armour potentially paves the way for a strategic relationship between the two companies, unlocking scientific and operational synergies, providing Transgene with another presence in the West giving it better access to more seasoned investors and strategic partners, and enabling Armour access to novel drug delivery technologies.
As a further signal of Transgene’s long term strategic geographical focus, the company has recently engaged HealthProBioVentures LLC, a New York based registered investment bank and strategic advisory firm that specializes in the life sciences industry.
Company Name | CMP |
---|---|
Apollo Hospital Ent. | 7036.65 |
Max Healthcare Inst | 1006.75 |
Narayana Hrudayalay | 1249.35 |
Aster DM Healthcare | 444.55 |
Global Health | 1115.50 |
View more.. |